Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Voyager Therapeutics Inc VYGR

Healthcare Biotechnology
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel... see more

Recent & Breaking News (NDAQ:VYGR)

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

GlobeNewswire April 16, 2024

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 26, 2024

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

GlobeNewswire March 13, 2024

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire February 28, 2024

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

GlobeNewswire February 26, 2024

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

GlobeNewswire February 21, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

GlobeNewswire February 20, 2024

Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference

GlobeNewswire February 7, 2024

Voyager Therapeutics Announces Pricing of Public Offering

GlobeNewswire January 4, 2024

Voyager Therapeutics Announces Proposed Public Offering

GlobeNewswire January 4, 2024

Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

GlobeNewswire January 2, 2024

Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

GlobeNewswire December 6, 2023

Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results

GlobeNewswire November 6, 2023

Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

GlobeNewswire October 30, 2023

Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference

GlobeNewswire September 25, 2023

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 7, 2023

Voyager Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 30, 2023

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 8, 2023

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

GlobeNewswire August 7, 2023